Latest Rosetta Genomics Ltd (ROSG) Headlines Up
Post# of 27
Posted On: 03/13/2014 2:02:11 AM
Latest Rosetta Genomics Ltd (ROSG) Headlines
Uptrend Call Working As Rosetta Genomics Stock Rises 100.7% (ROSG)
Comtex SmarTrend(R) - Wed Mar 12, 9:07AM CDT
SmarTrend identified an Uptrend for Rosetta Genomics (NASDAQ:ROSG) on December 5th, 2013 at $3.02. In approximately 3 months, Rosetta Genomics has returned 100.66% as of today's recent price of $6.06.
Rosetta Genomics Provides Product Pipeline Update
Marketwire - Wed Mar 12, 7:16AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces details regarding the Company's plans to advance its proprietary microRNA platform technologies in diagnostics and therapeutics.
Shares of Rosetta Genomics Receive a Boost, Up 6.4% - March 05, 2014
Comtex SmarTrend(R) - Wed Mar 05, 9:13AM CST
One of today's stocks on the move is Rosetta Genomics (NASDAQ:ROSG), up 6.4% to $5.48. The Dow Jones Industrial Average is now trading fractionally lower to 16,377 and the S&P is trading fractionally lower to 1,872.
Nasdaq stocks posting largest percentage increases
AP - Tue Mar 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Rosetta Genomics Has Returned 70.5% Since SmarTrend Recommendation (ROSG)
Comtex SmarTrend(R) - Tue Mar 04, 4:56PM CST
SmarTrend identified an Uptrend for Rosetta Genomics (NASDAQ:ROSG) on December 5th, 2013 at $3.02. In approximately 3 months, Rosetta Genomics has returned 70.53% as of today's recent price of $5.15.
Rosetta Genomics Announces Publication of Data Correlating miR-150 to Atrial Fibrillation in Patients With Chronic Systolic Heart Failure
Marketwire - Mon Mar 03, 8:15AM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces data from a study of the Company's microRNA technology was published online in the American Journal of Cardiology in an article entitled, "Relation of Reduced Expression of MiR-150 in Platelets to Atrial Fibrillation in Patients With Chronic Systolic Heart Failure." The abstract and full article can be accessed at http://www.ncbi.nlm.nih.gov/pubmed/24462065.
Rosetta Genomics expects US patent for oncology therapeutic associated with p53-negative patients
M2 - Thu Feb 27, 5:12AM CST
Molecular diagnostics company Rosetta Genomics (NASDAQ:ROSG) revealed on Wednesday the receipt of a Notice of Allowance for a patent claiming Mp53-negative cancer patients.
Rosetta Genomics to Receive Important U.S. Patent for Oncology Therapeutic
Marketwire - Wed Feb 26, 7:45AM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent claiming Mp53-negative cancer patients. The allowed claims for U.S. Patent Application No. 12/528,690 entitled "Composition and Methods for Modulating Cell Proliferation and Cell Death," cover a core element of Rosetta Genomics' microRNA technology in the development of cancer therapeutics associated with non-small cell lung cancer (NSCLC) in p53-negative patients. The allowed patent application is jointly owned with Yeda, the technology transfer company of the Weizmann Institute of Science in Rehovot, Israel.
Rosetta Genomics Executes Agreement With MultiPlan
Marketwire - Tue Feb 18, 7:45AM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has executed an agreement with Mulitiplan, Inc. (Multiplan) for Rosetta's healthcare services including the Rosetta Cancer Origin Test(TM).
Rosetta Genomics Appoints Kevin Watson as Director, Reimbursement-Managed Care
Marketwire - Tue Feb 18, 7:25AM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the appointment of Kevin Watson to the newly established role of Director, Reimbursement-Managed Care. Mr. Watson is a seasoned reimbursement specialist with nearly 25 years of experience in healthcare policy and reimbursement, managed care marketing, and new product development and commercialization.
Regeneron Announces Upcoming 2014 Investor Conference Presentations
PR Newswire - Fri Feb 14, 8:30AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:
Celebrate "Lamb Lovers Month" In February With Love Notes
PR Newswire - Fri Feb 07, 2:57PM CST
If you love ewe, it's time to count the ways. Or better yet, compose a love letter to the American Lamb Board during the month of February, "Lamb Lovers Month," for a chance to win a lamb lovers package.
Synopsys to Host First Developers Forum for Verdi Interoperable Apps (VIA) at SNUG Silicon Valley 2014
PR Newswire - Thu Jan 30, 8:00AM CST
Synopsys, Inc. (Nasdaq: SNPS), a global leader providing software, IP and services used to accelerate innovation in chips and electronic systems, today announced it will be hosting the inaugural Verdi Interoperable Apps (VIA) Developers Forum at SNUG Silicon Valley 2014 with the call for presentations for the forum now open. At this forum, SoC (system-on-chip) design teams from around the world can learn about further maximizing the effectiveness of Synopsys' Verdi® solution, the industry's de facto debug platform, with custom automation programs that leverage the underlying design analysis and debug infrastructure to increase SoC verification productivity.
Rosetta Cancer Origin Test Now Covered by Highmark Health Services, the Fourth Largest U.S. Blue Cross and Blue Shield-Affiliated Company
Marketwire - Tue Jan 21, 7:30AM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the Rosetta Cancer Origin Test(TM) has received in-network provider status with Highmark Health Services, a subsidiary of Highmark, Inc. This test for the identification of the tumor origin in Cancer of Unknown or Uncertain Primary (CUP) is now available to eligible Highmark Health Services members as an in-network service based on the individual member's benefits.
Rosetta Genomics' Platform Predicts Bladder Cancer Progression in Study Published in Urologic Oncology: Seminars and Original Investigations
Marketwire - Thu Jan 16, 6:55AM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the publication of clinical data in the online edition of Urologic Oncology: Seminars and Original Investigations in an article entitled, "The role of microRNA profiling in prognosticating progression in Ta and T1 urinary bladder cancer." The publication in its entirety can be viewed at http://www.urologiconcology.org/article/S1078...8/fulltext.
Uptrend Call Working As Rosetta Genomics Stock Rises 100.7% (ROSG)
Comtex SmarTrend(R) - Wed Mar 12, 9:07AM CDT
SmarTrend identified an Uptrend for Rosetta Genomics (NASDAQ:ROSG) on December 5th, 2013 at $3.02. In approximately 3 months, Rosetta Genomics has returned 100.66% as of today's recent price of $6.06.
Rosetta Genomics Provides Product Pipeline Update
Marketwire - Wed Mar 12, 7:16AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces details regarding the Company's plans to advance its proprietary microRNA platform technologies in diagnostics and therapeutics.
Shares of Rosetta Genomics Receive a Boost, Up 6.4% - March 05, 2014
Comtex SmarTrend(R) - Wed Mar 05, 9:13AM CST
One of today's stocks on the move is Rosetta Genomics (NASDAQ:ROSG), up 6.4% to $5.48. The Dow Jones Industrial Average is now trading fractionally lower to 16,377 and the S&P is trading fractionally lower to 1,872.
Nasdaq stocks posting largest percentage increases
AP - Tue Mar 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Rosetta Genomics Has Returned 70.5% Since SmarTrend Recommendation (ROSG)
Comtex SmarTrend(R) - Tue Mar 04, 4:56PM CST
SmarTrend identified an Uptrend for Rosetta Genomics (NASDAQ:ROSG) on December 5th, 2013 at $3.02. In approximately 3 months, Rosetta Genomics has returned 70.53% as of today's recent price of $5.15.
Rosetta Genomics Announces Publication of Data Correlating miR-150 to Atrial Fibrillation in Patients With Chronic Systolic Heart Failure
Marketwire - Mon Mar 03, 8:15AM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces data from a study of the Company's microRNA technology was published online in the American Journal of Cardiology in an article entitled, "Relation of Reduced Expression of MiR-150 in Platelets to Atrial Fibrillation in Patients With Chronic Systolic Heart Failure." The abstract and full article can be accessed at http://www.ncbi.nlm.nih.gov/pubmed/24462065.
Rosetta Genomics expects US patent for oncology therapeutic associated with p53-negative patients
M2 - Thu Feb 27, 5:12AM CST
Molecular diagnostics company Rosetta Genomics (NASDAQ:ROSG) revealed on Wednesday the receipt of a Notice of Allowance for a patent claiming Mp53-negative cancer patients.
Rosetta Genomics to Receive Important U.S. Patent for Oncology Therapeutic
Marketwire - Wed Feb 26, 7:45AM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent claiming Mp53-negative cancer patients. The allowed claims for U.S. Patent Application No. 12/528,690 entitled "Composition and Methods for Modulating Cell Proliferation and Cell Death," cover a core element of Rosetta Genomics' microRNA technology in the development of cancer therapeutics associated with non-small cell lung cancer (NSCLC) in p53-negative patients. The allowed patent application is jointly owned with Yeda, the technology transfer company of the Weizmann Institute of Science in Rehovot, Israel.
Rosetta Genomics Executes Agreement With MultiPlan
Marketwire - Tue Feb 18, 7:45AM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has executed an agreement with Mulitiplan, Inc. (Multiplan) for Rosetta's healthcare services including the Rosetta Cancer Origin Test(TM).
Rosetta Genomics Appoints Kevin Watson as Director, Reimbursement-Managed Care
Marketwire - Tue Feb 18, 7:25AM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the appointment of Kevin Watson to the newly established role of Director, Reimbursement-Managed Care. Mr. Watson is a seasoned reimbursement specialist with nearly 25 years of experience in healthcare policy and reimbursement, managed care marketing, and new product development and commercialization.
Regeneron Announces Upcoming 2014 Investor Conference Presentations
PR Newswire - Fri Feb 14, 8:30AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:
Celebrate "Lamb Lovers Month" In February With Love Notes
PR Newswire - Fri Feb 07, 2:57PM CST
If you love ewe, it's time to count the ways. Or better yet, compose a love letter to the American Lamb Board during the month of February, "Lamb Lovers Month," for a chance to win a lamb lovers package.
Synopsys to Host First Developers Forum for Verdi Interoperable Apps (VIA) at SNUG Silicon Valley 2014
PR Newswire - Thu Jan 30, 8:00AM CST
Synopsys, Inc. (Nasdaq: SNPS), a global leader providing software, IP and services used to accelerate innovation in chips and electronic systems, today announced it will be hosting the inaugural Verdi Interoperable Apps (VIA) Developers Forum at SNUG Silicon Valley 2014 with the call for presentations for the forum now open. At this forum, SoC (system-on-chip) design teams from around the world can learn about further maximizing the effectiveness of Synopsys' Verdi® solution, the industry's de facto debug platform, with custom automation programs that leverage the underlying design analysis and debug infrastructure to increase SoC verification productivity.
Rosetta Cancer Origin Test Now Covered by Highmark Health Services, the Fourth Largest U.S. Blue Cross and Blue Shield-Affiliated Company
Marketwire - Tue Jan 21, 7:30AM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the Rosetta Cancer Origin Test(TM) has received in-network provider status with Highmark Health Services, a subsidiary of Highmark, Inc. This test for the identification of the tumor origin in Cancer of Unknown or Uncertain Primary (CUP) is now available to eligible Highmark Health Services members as an in-network service based on the individual member's benefits.
Rosetta Genomics' Platform Predicts Bladder Cancer Progression in Study Published in Urologic Oncology: Seminars and Original Investigations
Marketwire - Thu Jan 16, 6:55AM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the publication of clinical data in the online edition of Urologic Oncology: Seminars and Original Investigations in an article entitled, "The role of microRNA profiling in prognosticating progression in Ta and T1 urinary bladder cancer." The publication in its entirety can be viewed at http://www.urologiconcology.org/article/S1078...8/fulltext.
(0)
(0)Rosetta Genomics, Ltd. (ROSGQ) Stock Research Links
Scroll down for more posts ▼